

Change in Boardroom

IHH HEALTHCARE BERHAD

Date of change	01 Jul 2019
Name	DR KELVIN LOH CHI-KEON
Age	45
Gender	Male
Nationality	Singapore
Designation	Executive Director
Directorate	Executive
Type of change	Appointment

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Masters	Business Administration	National University of Singapore Business School	
2	Degree	Bachelor of Medicine and Bachelor of Surgery	National University of Singapore	

Working experience and occupation

Dr Kelvin Loh Chi-Keon ("Dr Kelvin Loh") joins IHH Healthcare Berhad ("IHH") from Columbia Asia Group where he was Chief Executive Officer ("CEO"). Dr Kelvin Loh started his career as a practicing physician before serving for 10 years in the public sector in Singapore, in areas such as clinical services development, hospital planning and hospital operations.

Dr Kelvin Loh previously joined the IHH Group in 2008, and between 2008 and 2017 held a number of senior management roles, before taking over as CEO for the Singapore Operations Division, covering among other services, the 4 multi-specialty tertiary hospitals - Mount Elizabeth, Mount Elizabeth Novena, Gleneagles and Parkway East.

Dr Kelvin Loh moved to Columbia Asia Group as CEO in 2017 where he was responsible for overseeing Columbia Asia Group's 28 hospitals across 4 countries in Asia including Malaysia and India.

Dr Kelvin Loh is a senior healthcare executive with strong track record of delivery. He has extensive experience in leading large healthcare businesses, building relationships with stakeholders, managing hospital operations, financial management and developing people. He is also deeply familiar with the healthcare operating context in diverse countries across Asia.

Directorships in public companies and listed issuers (if any)

Nil

Family relationship with any director and/or major shareholder of the listed issuer

Nil

Any conflict of interests that he/she has with the listed issuer

Nil

Details of any interest in the securities of the listed issuer or its subsidiaries

Dr Kelvin Loh's interest as at 27 May 2019 is as follows:

Direct interest in a subsidiary:
Parkway Life Real Estate Investment Trust - 120,000 units

Remarks :

Dr Kelvin Loh will assume the position of Managing Director and Chief Executive Officer of IHH with effect from 1 January 2020, to succeed Dr Tan See Leng upon the completion of his contract period on 31 December 2019. Prior to the effective date of his appointment on 1 January 2020, Dr Kelvin Loh will be joining the IHH Group as CEO (designate) and Executive Director to undertake a transitional process from 1 July 2019 onwards.

Announcement Info

Company Name	IHH HEALTHCARE BERHAD
---------------------	-----------------------

Stock Name	IHH
-------------------	-----

Date Announced	27 May 2019
-----------------------	-------------

Category	Change in Boardroom
-----------------	---------------------

Reference Number	C03-27052019-00002
-------------------------	--------------------
